Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent

Soo G. Kim, Samuel D. Felder, Ilona Figura, Debra R. Johnston, Anthony D. Mercando, John Devens Fisher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT). At baseline all patients had VT inducible by programmed stimulation. After amiodarone loading (935 ± 271 mg/day for 16 ± 7 days), efficacy of amiodarone was determined by 3 programmed stimulation criteria (criterion I = VT not inducible or 15 beats or less; criterion II = VT not inducible or harder to induce; criterion III = VT not easier to induce). Amiodarone was effective in 12, 25 and 49 of 70 patients by criteria I, II and III, respectively. There were 16 recurrences or cardiac arrest during the follow-up period (19 ± 19 months). Actuarial arrhythmia-free survival rates at 1 and 2 years were: 90% and 90% in patients with efficacy by criterion I and 78% and 78% in patients with inefficacy, respectively; 84 % and 84% in patients with efficacy by criterion II and 78% and 78% in patients with inefficacy, respectively; and 80% and 80% in patients with efficacy by criterion III and 79% and 79% in patients with inefficacy, respectively (difference not significant for all). From the results of follow-up at 2 years, sensitivities of criteria I, II and III were 92%, 75% and 33%, respectively. Specificities were 17%, 26% and 70%, respectively, and predictive accuracies were 43%, 43% and 67%, respectively. Thus, patients with efficacy by criterion I appear to have a better prognosis when compared with patients with inefficacy. However, many patients with inefficacy by criterion I had a good outcome (nonspecificity). Criteria II and III based on the changes in the mode of VT induction may not predict clinical outcomes. Criterion II is sensitive but nonspecific and criterion III is specific but insensitive.

Original languageEnglish (US)
Pages (from-to)1314-1318
Number of pages5
JournalThe American Journal of Cardiology
Volume59
Issue number15
DOIs
StatePublished - Jun 1 1987

Fingerprint

Amiodarone
Ventricular Tachycardia
Therapeutics
Heart Arrest
Cardiac Arrhythmias
Survival Rate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent. / Kim, Soo G.; Felder, Samuel D.; Figura, Ilona; Johnston, Debra R.; Mercando, Anthony D.; Fisher, John Devens.

In: The American Journal of Cardiology, Vol. 59, No. 15, 01.06.1987, p. 1314-1318.

Research output: Contribution to journalArticle

@article{872930478bc5462e8a0888ced87f58db,
title = "Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent",
abstract = "The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT). At baseline all patients had VT inducible by programmed stimulation. After amiodarone loading (935 ± 271 mg/day for 16 ± 7 days), efficacy of amiodarone was determined by 3 programmed stimulation criteria (criterion I = VT not inducible or 15 beats or less; criterion II = VT not inducible or harder to induce; criterion III = VT not easier to induce). Amiodarone was effective in 12, 25 and 49 of 70 patients by criteria I, II and III, respectively. There were 16 recurrences or cardiac arrest during the follow-up period (19 ± 19 months). Actuarial arrhythmia-free survival rates at 1 and 2 years were: 90{\%} and 90{\%} in patients with efficacy by criterion I and 78{\%} and 78{\%} in patients with inefficacy, respectively; 84 {\%} and 84{\%} in patients with efficacy by criterion II and 78{\%} and 78{\%} in patients with inefficacy, respectively; and 80{\%} and 80{\%} in patients with efficacy by criterion III and 79{\%} and 79{\%} in patients with inefficacy, respectively (difference not significant for all). From the results of follow-up at 2 years, sensitivities of criteria I, II and III were 92{\%}, 75{\%} and 33{\%}, respectively. Specificities were 17{\%}, 26{\%} and 70{\%}, respectively, and predictive accuracies were 43{\%}, 43{\%} and 67{\%}, respectively. Thus, patients with efficacy by criterion I appear to have a better prognosis when compared with patients with inefficacy. However, many patients with inefficacy by criterion I had a good outcome (nonspecificity). Criteria II and III based on the changes in the mode of VT induction may not predict clinical outcomes. Criterion II is sensitive but nonspecific and criterion III is specific but insensitive.",
author = "Kim, {Soo G.} and Felder, {Samuel D.} and Ilona Figura and Johnston, {Debra R.} and Mercando, {Anthony D.} and Fisher, {John Devens}",
year = "1987",
month = "6",
day = "1",
doi = "10.1016/0002-9149(87)90911-8",
language = "English (US)",
volume = "59",
pages = "1314--1318",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "15",

}

TY - JOUR

T1 - Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent

AU - Kim, Soo G.

AU - Felder, Samuel D.

AU - Figura, Ilona

AU - Johnston, Debra R.

AU - Mercando, Anthony D.

AU - Fisher, John Devens

PY - 1987/6/1

Y1 - 1987/6/1

N2 - The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT). At baseline all patients had VT inducible by programmed stimulation. After amiodarone loading (935 ± 271 mg/day for 16 ± 7 days), efficacy of amiodarone was determined by 3 programmed stimulation criteria (criterion I = VT not inducible or 15 beats or less; criterion II = VT not inducible or harder to induce; criterion III = VT not easier to induce). Amiodarone was effective in 12, 25 and 49 of 70 patients by criteria I, II and III, respectively. There were 16 recurrences or cardiac arrest during the follow-up period (19 ± 19 months). Actuarial arrhythmia-free survival rates at 1 and 2 years were: 90% and 90% in patients with efficacy by criterion I and 78% and 78% in patients with inefficacy, respectively; 84 % and 84% in patients with efficacy by criterion II and 78% and 78% in patients with inefficacy, respectively; and 80% and 80% in patients with efficacy by criterion III and 79% and 79% in patients with inefficacy, respectively (difference not significant for all). From the results of follow-up at 2 years, sensitivities of criteria I, II and III were 92%, 75% and 33%, respectively. Specificities were 17%, 26% and 70%, respectively, and predictive accuracies were 43%, 43% and 67%, respectively. Thus, patients with efficacy by criterion I appear to have a better prognosis when compared with patients with inefficacy. However, many patients with inefficacy by criterion I had a good outcome (nonspecificity). Criteria II and III based on the changes in the mode of VT induction may not predict clinical outcomes. Criterion II is sensitive but nonspecific and criterion III is specific but insensitive.

AB - The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT). At baseline all patients had VT inducible by programmed stimulation. After amiodarone loading (935 ± 271 mg/day for 16 ± 7 days), efficacy of amiodarone was determined by 3 programmed stimulation criteria (criterion I = VT not inducible or 15 beats or less; criterion II = VT not inducible or harder to induce; criterion III = VT not easier to induce). Amiodarone was effective in 12, 25 and 49 of 70 patients by criteria I, II and III, respectively. There were 16 recurrences or cardiac arrest during the follow-up period (19 ± 19 months). Actuarial arrhythmia-free survival rates at 1 and 2 years were: 90% and 90% in patients with efficacy by criterion I and 78% and 78% in patients with inefficacy, respectively; 84 % and 84% in patients with efficacy by criterion II and 78% and 78% in patients with inefficacy, respectively; and 80% and 80% in patients with efficacy by criterion III and 79% and 79% in patients with inefficacy, respectively (difference not significant for all). From the results of follow-up at 2 years, sensitivities of criteria I, II and III were 92%, 75% and 33%, respectively. Specificities were 17%, 26% and 70%, respectively, and predictive accuracies were 43%, 43% and 67%, respectively. Thus, patients with efficacy by criterion I appear to have a better prognosis when compared with patients with inefficacy. However, many patients with inefficacy by criterion I had a good outcome (nonspecificity). Criteria II and III based on the changes in the mode of VT induction may not predict clinical outcomes. Criterion II is sensitive but nonspecific and criterion III is specific but insensitive.

UR - http://www.scopus.com/inward/record.url?scp=0023223360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023223360&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90911-8

DO - 10.1016/0002-9149(87)90911-8

M3 - Article

VL - 59

SP - 1314

EP - 1318

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 15

ER -